Bio-Rad Third-Quarter 2026 Earnings Results Conference Call and Webcast - BIO-RAD LABORATORIES INC

Explicit Guidance:

• FY2026 Currency-Neutral Revenue Growth: Reaffirmed range of -3% to +0.5%; expected to finish near the midpoint of the range.
• FY2026 Segment Revenue Growth:
  • Life Science: -3% to -1% currency-neutral.
  • Clinical Diagnostics: -3% to +1% currency-neutral.
• FY2026 Sequential Revenue Ramp: Expected 5–6% increase from Q3 to Q4 on a reported basis (aligned with typical seasonality).
• FY2026 Non-GAAP Gross Margin: Expected to finish in the upper half of the 53%–54% range (targeting 53.5%–54%).
  • Q4 2026 Margin Pressure: Expects a sequential decline in Q4 due to product mix shifts toward instruments, continued decline in process chromatography revenue, and higher fuel prices expected to persist into 2027.
• FY2026 Non-GAAP Operating Margin: Expected to finish in the upper half of the 10%–12% range (targeting 11%–12%).
• FY2026 Non-GAAP Free Cash Flow: Reaffirmed estimate of $290–$340 million. (Note: $210 million generated in first nine months; Q4 is seasonally strongest).
• Q4 2026 Expense Outlook:
  • SG&A: Flat to Q3 2026.
  • R&D: Sequential step-up of $3 million to support continued innovation.
  • Depreciation/Amortization: Approximately $40 million.
• FY2027 Outlook: No specific numerical guidance provided; management aims to return to positive revenue growth and further margin expansion.
• Tariff Refunds: Any refunded tariffs recognized in year-end 2026 GAAP results (excluded from Non-GAAP).

Business-Segment Outlook:

• DDPCR (Droplet Digital PCR): Continued confidence in DDP-CR as a "durable growth driver" for many years. Despite potential cycle-up in comparisons, the portfolio is expected to expand the market served and drive near-to-midterm growth via customer wins and increased system utilization.
• Process Chromatography: Sequential revenue decline expected in Q4 2026; FY2026 revenue expected to improve year-over-year. Recovery in demand is viewed as gradual.
• Academic & Government Markets: Conditions remain challenging; fourth quarter outlook assumes no recovery in these end markets. Continued pressure expected from NIH outlays and funding constraints into 2027.
• Clinical Diagnostics: Growth driven by Quality Systems and Diabetes products.
• China Market: Performance expected to face pricing pressure from National Healthcare Security Administration guidelines. Estimated revenue impact in 2027 in the middle single-digit millions of dollars. Continued preference for domestic suppliers anticipated.
• Middle East: Logistics costs and supply chain disruptions expected to continue into 2027, requiring continued product availability management.

Market and Competitive Outlook:

• Biopharma: Signs of improving customer activity; recovery viewed as gradual. Transition observed from later-stage large pharma/biotech to more discovery roles.
• AI Impact: Management views AI as a positive demand driver for the portfolio, specifically supporting the transition from in silico modeling to wet-lab work, leading to more productive testing and higher reagent utilization in both academic and drug discovery sectors.
• PAMA (Medicare Reimbursement): No meaningful change in customer purchasing behavior observed to date; any indirect impact on business in 2027 expected to be limited.
• China Competitive Landscape: Ongoing pricing pressure and preference for domestic suppliers affecting the in vitro diagnostics market.

Macro / Industry Outlook:

• US Academic/Government: Continued funding challenges with NIH outlays declining ~15% in Q3; no expected recovery in 2026 Q4 outlook.
• Supply Chain/Fuel: Elevated logistics costs (Middle East) and higher fuel prices expected to persist into 2027, impacting margin.
• Regulatory (China): New National Healthcare Security Administration guidelines creating pricing headwinds with measurable revenue impact in 2027.
• Currency: Management noted Q3 as the first quarter of currency-neutral growth in the year; FX continues to be a factor in reporting.

Strategic Initiatives:

• Cost Restructuring: Executing on the $80M–$90M program; net savings target of $30–$35 million remains intact. Full realization of savings expected starting in 2028 (actions take hold late 2026 and throughout 2027).
• AI Integration: Dual focus on improving internal operations/productivity and enhancing product capabilities. AI-driven algorithms deployed in new products (e.g., ChemiDot Pro) to improve image analysis consistency.
• Product Innovation: Continued focus on a predictable cadence of innovation.
  • ChemiDot Pro: Launched new flagship Western blot imaging platform (accelerated by two quarters via R&D prioritization).
  • Foresight Pro: Expanded pre-packed chromatography columns with Renuvia resins.
  • Portfolio Management: Disciplined approach to eliminating low-ROI programs; non-cash impairment of $50M intangible assets recorded in Q3.
• Capital Allocation:
  • M&A: Not seeking transformative deals; targeting opportunities with $100M–$500M revenue in Diagnostics or Life Science that offer differentiation, top-line growth, and margin/working capital efficiency.
  • Share Repurchases: Continuing to be opportunistic rather than systematic; company views stock as undervalued.
  • Sartorius AG Stake: Remains a monetizable asset; no change in strategy regarding potential monetization.
• Board Refresh: Actively evaluating candidates to expand board diversity and operational experience in Life Science and Diagnostics; updates expected in the near future.

Risks and Headwinds to Outlook:

• Academic/Government Funding: Persistent softness in US academic and government end markets (NIH outlays) could delay recovery.
• China Pricing/Geopolitics: Regulatory guidelines and domestic supplier preferences in China may suppress pricing and volume in 2027.
• Supply Chain/Fuel: Elevated logistics costs (Middle East) and fuel price inflation expected to continue into 2027, impacting margins.
• PAMA Implementation: Uncertainty regarding final Medicare reimbursement rates and potential indirect impact on customer purchasing economics in 2027.
• Market Cycles: DDPCR growth may face more challenging year-over-year comparisons in the future as the base expands.
• Restructuring Timeline: Full financial benefit of cost savings ($30–$35M) delayed until 2028.

Management Tone on the Future:

• Confidence Level: Encouraged by progress (currency-neutral growth return, DDPCR strength, margin improvement) but acknowledges "mixed" and "uneven" end markets.
• Strategic Focus: Emphasis on "consistent organic growth, improved profitability, and strengthening execution."
• Long-Term View: Firm belief in the capability to deliver operating margins above 20%; current performance is viewed as below this potential.
• Guidance vs. Prior: Reaffirmed 2026 guidance while noting continued softness in specific segments; cautious on 2027 recovery but committed to positive growth trajectory.

Miscellaneous:

• Non-GAAP Adjustments: Q3 results include $50M non-cash impairment of intangible assets and restructuring charges. Non-GAAP measures exclude changes in equity value of Sartorius AG stake.
• Tariff Policy: Company absorbs all tariff surcharges in COGS; any future refunds will be recognized on a GAAP basis only and not passed to customers.
• Investor Relations: Management to attend UBS Global Healthcare Conference next week.